Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Brotchie

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Neuroscience|April 20, 2001
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeyE Bezard, T Boraud, S Chalon, et al.
Experimental Neurology|May 1, 1996
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's diseaseY P Maneuf, S Duty, C J Hille, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 6, 2000
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's diseaseV Di Marzo, M P Hill, T Bisogno, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 11, 2005
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesiaJ E Nash, T H Johnston, G L Collingridge, et al.
Brain Research|June 12, 1995
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's diseaseY P Maneuf, I J Mitchell, A R Crossman, et al.
Experimental Neurology|October 30, 2001
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's diseaseC J Hille, S H Fox, Y P Maneuf, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 29, 2008
Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquesN P Visanji, S H Fox, T H Johnston, et al.
Neuroscience|September 11, 2007
High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleusD S Shin, M Samoilova, M Cotic, et al.
Experimental Neurology|July 13, 2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, P Ravenscroft, S McGuire, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxanS H Fox, B Henry, M P Hill, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Neuroscience|April 20, 2001
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeyE Bezard, T Boraud, S Chalon, et al.
Experimental Neurology|May 1, 1996
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's diseaseY P Maneuf, S Duty, C J Hille, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 6, 2000
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's diseaseV Di Marzo, M P Hill, T Bisogno, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 11, 2005
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesiaJ E Nash, T H Johnston, G L Collingridge, et al.
Brain Research|June 12, 1995
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's diseaseY P Maneuf, I J Mitchell, A R Crossman, et al.
Experimental Neurology|October 30, 2001
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's diseaseC J Hille, S H Fox, Y P Maneuf, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 29, 2008
Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquesN P Visanji, S H Fox, T H Johnston, et al.
Neuroscience|September 11, 2007
High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleusD S Shin, M Samoilova, M Cotic, et al.
Experimental Neurology|July 13, 2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, P Ravenscroft, S McGuire, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxanS H Fox, B Henry, M P Hill, et al.
Pageof 6